Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) is moving fast to modernize its regulatory framework. With an aging population and rapid technological advances in AI, software, and regenerative medicine, the country is balancing two goals: maintaining rigorous safety standards while accelerating access to innovative treatments.
This article breaks down the most critical 2026 compliance deadlines, new software approval pathways, and groundbreaking medical product approvals you need to know about. Whether you’re preparing a regulatory submission or simply keeping up with the market, here’s what’s changing.
February 2026 Deadline: The New EMC Standards Transition
Japan has set a hard deadline for transitioning to updated Electromagnetic Compatibility (EMC) standards for medical devices. Starting February 25, 2026, any medical device manufactured and marketed in Japan must comply with the new JIS T 0601-1-2:2023 standard.
Here’s what this means: if your device was manufactured before February 24, 2026, you can continue using either the old standard (JIS T 0601-1-2:2018) or the new one. But any device produced on or after February 25, 2026, must meet the updated requirements.
The PMDA isn’t just checking boxes. For devices submitted for approval after the deadline, you’ll need to include documentation showing compliance with the new EMC standard at the time of application.
Even for devices already on the market under the old standard, risk management assessments are required to determine whether additional testing or re-evaluation is necessary.
This is more than a paperwork update. Manufacturers should review their current risk management processes now to ensure they align with JIS T 14971 and identify any gaps that need to be addressed before the February deadline.
Fast-Tracking Software as a Medical Device (SaMD) and AI Tools
Japan is serious about catching up with global leaders in digital health. In September 2023, the Ministry of Health, Labour and Welfare (MHLW) launched “DASH for SaMD 2,” a five-year strategy designed to accelerate the development and approval of Software as a Medical Device (SaMD).
One of the most significant changes is the implementation of a two-stage approval system for SaMD, which went into effect in 2024. Here’s how it works:
Stage 1 (Initial Approval): If a software product demonstrates reliable performance in testing and shows safety plus a reasonable level of efficacy based on non-clinical or early-stage data, it can receive initial approval. This is especially relevant for therapeutic SaMD aimed at alleviating specific symptoms.
Stage 2 (Full Approval): After the product is used in real-world settings, manufacturers collect additional clinical evidence and real-world data to confirm the final clinical benefit. Once this data is reviewed and approved, the product receives full approval.
This pathway allows innovative AI diagnostic tools and digital therapeutics to reach patients faster while still requiring robust post-market evidence. For companies developing SaMD, this is a major opportunity—but it also means you’ll need a solid plan for collecting and reporting real-world performance data.
eCTD 4.0: The Digital Shift for Regulatory Submissions in 2026
Japan is upgrading its digital infrastructure for regulatory submissions. Starting April 1, 2026, the PMDA will only accept new drug applications in eCTD version 4.0 format. Submissions in older formats, such as eCTD v3.2.2, will no longer be accepted after that date.
This shift is part of a broader move toward structured data and lifecycle management. The new eCTD 4.0 format improves the organization and accessibility of regulatory information, making it easier for the PMDA to review submissions and for companies to manage updates over a product’s lifecycle.
If you’re planning to submit a new drug or medical device application in Japan, now is the time to upgrade your Quality Management Systems (QMS) and digital submission infrastructure.
The PMDA has already been running validation tests, and companies should ensure they’re using the correct validation rules and engine versions to avoid delays.
PMD Act Revisions & Evolving Reimbursement Rules
Japan’s Pharmaceutical and Medical Device Act (PMD Act) underwent significant revisions in May 2025, with full implementation expected by May 2027.
Stricter Safety and Quality Requirements: Marketing Authorization Holders (MAHs) are now required to appoint both a Safety Manager and a Quality Manager. Additionally, MAHs must implement more detailed adverse event collection programs. If quality issues arise, the MHLW has the authority to require MAHs to change their key responsible personnel.
Supply Chain Accountability: The updated PMD Act also requires MAHs to designate a Supply System Manager who is responsible for monitoring and reporting supply chain disruptions to the MHLW in a timely manner. This change addresses recent concerns about shortages of critical medical products.
Reimbursement Shifts: Japan’s reimbursement council, Chuikyo, is moving away from relying heavily on Foreign Reference Pricing (FRP). In the past, reimbursement was often determined by comparing prices across the US, UK, France, Germany, and Australia. Now, Chuikyo is prioritizing clinical value and patient outcomes over price comparisons alone.
For manufacturers, this means demonstrating superior clinical efficacy and real-world benefits is more important than ever. Products that show meaningful improvements in patient outcomes are more likely to receive favorable reimbursement, while those that rely solely on foreign pricing data may face reductions.
Breaking News: World’s First iPS Cell Medical Products
In February 2026, a Japanese expert panel greenlit two regenerative medical products using induced pluripotent stem (iPS) cells—marking the world’s first approvals of their kind.
ReHeart: A cardiac muscle sheet developed for treating severe heart failure. The product is made from third-party iPS cells and is applied to damaged heart tissue to promote blood vessel regeneration.
Amchepry: A neural cell therapy for Parkinson’s disease. The treatment involves transplanting neural precursor cells derived from iPS cells into the brain to produce dopamine and improve symptoms.
Both products were approved under Japan’s conditional and time-limited approval system, which allows promising regenerative therapies to reach patients faster.
Under this system, manufacturers must collect safety and efficacy data from all cases over a seven-year approval period. During this time, ReHeart is expected to be used in 75 patients, while Amchepry will be used in 35 patients (30 of whom must be 65 or younger).
At the end of the seven years, the products will undergo another assessment to obtain final approval. This approach balances patient access with ongoing safety monitoring, reflecting Japan’s commitment to both innovation and rigorous oversight.
Frequently Asked Questions (FAQ)
What is a Marketing Authorization Holder (MAH) in Japan?
A Marketing Authorization Holder (MAH) is a locally licensed entity that holds legal responsibility for a medical device’s safety, quality, and regulatory compliance in Japan.
Foreign companies cannot sell medical devices directly in Japan—they must appoint a Japanese MAH (or a Designated MAH) to handle regulatory submissions and post-market obligations.
How are medical devices classified in Japan?
Japan classifies medical devices into four risk-based categories:
- Class I: General medical devices with minimal risk (notification required)
- Class II: Controlled medical devices requiring certification
- Class III: Controlled medical devices requiring approval
- Class IV: Specially-controlled medical devices requiring full PMDA approval
The classification determines the level of regulatory scrutiny and the type of submission required.
Are foreign clinical trials accepted by the PMDA?
Yes, the PMDA accepts foreign clinical data, provided the studies comply with Japanese Good Clinical Practices (GCP) or equivalent international standards.
However, companies must demonstrate that the data is applicable to the Japanese population, taking into account factors like race, cultural background, and disease characteristics. In some cases, additional Japanese clinical data may be required.
Japan is Raising the Bar, and Rolling Out the Red Carpet
Japan’s 2026 regulatory landscape reflects a careful balancing act. On one hand, the country is raising compliance standards with stricter EMC requirements, updated submission formats, and enhanced post-market safety obligations.
On the other hand, Japan is actively welcoming innovation through fast-track pathways for SaMD, conditional approvals for regenerative medicine, and a reimbursement system that rewards clinical value.
For companies navigating this environment, the message is clear: rigorous preparation and clinical evidence are non-negotiable, but the opportunities for innovative, patient-centered technologies have never been greater.
Sources
